Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Integrated Anthelmintic-Based control of Taenia solium cysticercosis/taeniasis, Soil-transmitted Helminthiasis and Schistosomiasis: safety, effectiveness and implementation strategies

Project description

New strategy to tackle neglected tropical diseases

Control programmes targeting soil-transmitted helminths (STH) and schistosomiasis (SCH) have been in place for years, but falling drug efficacy and growing resistance are undermining their success. Meanwhile, Taenia solium, which is linked to serious neurological illness, remains largely neglected, with no routine interventions. In this context, the EU-funded 3SI-CONTROL project is addressing these gaps by testing a novel fixed-dose combination of albendazole, ivermectin, and praziquantel. Through a large clinical trial and embedded implementation research, the project will assess the safety, cost-effectiveness, and real-world viability of an integrated treatment strategy. By combining scientific evidence with strong advocacy, 3SI-CONTROL aims to inform global health policy and improve control of three major neglected tropical diseases in underserved communities.

Objective

Control of soil transmitted helminths (STH) and Schistosomiasis (SCH) has been part of routine programmes for many years, yet, the efficacy and effectiveness of these programmes is challenged by low and failing drug efficacy and growing concerns of anthelmintic resistance, calling for a revision of the MDA-drug strategies. In this regard, the novel fixed-dose co-formulation (FDC) including albendazole and ivermectin has proven to be safe and to overcome most of the challenges in drug efficacy for STH. For T. solium the situation is very different from STH and SCH as currently there are no countries routinely implementing control. 3SI-CONTROL will assess the safety and cost-effectiveness of the FDC co-administration with praziquantel in reducing the prevalence of T. solium, STH and SCH, in a randomised controlled trial embedded in solid implementation research. Results from 3SI-CONTROL will thereby provide a scientific evidence base on the safety and effectiveness of integration of T. solium control with STH and SCH, considering the One Health approach. Beyond this, the substantial implementation research component will enable bridging the gap between the evidence-based practice (results on safety and effectiveness) and the actual implementation in the routine, real-world setting. These results, joined by a comprehensive dissemination and advocacy plan, will provide leverage to stimulate uptake of T. solium in the existing routine NTD control programmes, enabling the implementation of a safe and integrated control strategy with a higher effectiveness, tackling three top ranking NTDs. By harnessing advanced concepts in One Health, implementation research, and pharmacovigilance, our project aims to deliver transformative impacts in NTD control, reducing the individual, social and economic burdens of resource poor rural populations.

Fields of science (EuroSciVoc)

This project has not yet been classified with EuroSciVoc.
Be the first one to suggest relevant scientific fields and help us improve our classification service

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-JU-RIA - HORIZON JU Research and Innovation Actions

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-JU-GH-EDCTP3-2024-01-two-stage

See all projects funded under this call

Coordinator

UNIVERSITEIT GENT
Net EU contribution
€ 1 288 775,00
Address
SINT PIETERSNIEUWSTRAAT 25
9000 Gent
Belgium
Region
Vlaams Gewest Prov. Oost-Vlaanderen Arr. Gent
Activity type
Higher or Secondary Education Establishments
Links
Total cost
€ 1 288 775,00

Participants (6)